Codagenix Inc.

Curie.Bio launched on 14 February with $520m to provide $5m-$7m in seed financing per start-up, plus access to in-house expertise and external research services, to help new biopharmas generate enough

Codagenix Inc. ’s platform technology combining live-attenuated virus design with AI-assisted codon deoptimization technology presents several possibilities for vaccines and therapeutics. Hopefully 20

White House officials have high expectations for the next generation of COVID-19 vaccines, a bar that may prove difficult to meet. Shifting market dynamics and a less hospitable research environment a

An expert panel is assessing whether two more candidate COVID-19 vaccines, from Arcturus and Codagenix, should be added to the global Solidarity Trial Vaccines (STV) initiative, which has been set up